Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women

Open access

Abstract

BACKGROUND: How antimalarial antibodies are acquired and maintained during pregnancy and boosted after reinfection with Plasmodium falciparum and Plasmodium vivax is unknown. METHODS: A nested case-control study of 467 pregnant women (136 Plasmodium-infected cases and 331 uninfected control subjects) in northwestern Thailand was conducted. Antibody levels to P. falciparum and P. vivax merozoite antigens and the pregnancy-specific PfVAR2CSA antigen were determined at enrollment (median 10 weeks gestation) and throughout pregnancy until delivery. RESULTS: Antibodies to P. falciparum and P. vivax were highly variable over time, and maintenance of high levels of antimalarial antibodies involved highly dynamic responses resulting from intermittent exposure to infection. There was evidence of boosting with each successive infection for P. falciparum responses, suggesting the presence of immunological memory. However, the half-lives of Plasmodium antibody responses were relatively short, compared with measles (457 years), and much shorter for merozoite responses (0.8-7.6 years), compared with PfVAR2CSA responses (36-157 years). The longer half-life of antibodies to PfVAR2CSA suggests that antibodies acquired in one pregnancy may be maintained to protect subsequent pregnancies. CONCLUSIONS: These findings may have important practical implications for predicting the duration of vaccine-induced responses by candidate antigens and supports the development of malaria vaccines to protect pregnant women.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/infdis/jis566

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Antibodies to Plasmodium species blood-stage antigens at enrollment. Antibody levels were determined in all available case (n = 124) and control (n = 320) samples at enrollment (median 10 weeks gestation). (A) Seroprevalence with standard errors and (B) boxplots of antibody levels in case and control subjects. Horizontal lines represent medians, boxes represent interquartile range, and lines represent ranges with outliers represented as dots. Antibody prevalences and levels were significantly higher in case than in control subjects (P < .001). Antibody levels according to gravidity in control subjects (C) and case subjects (D). In case and control groups, there was no association between gravidity and antibody levels (P > .17).
Figure 1. Antibodies to Plasmodium species blood-stage antigens at enrollment. Antibody levels were determined in all available case (n = 124) and control (n = 320) samples at enrollment (median 10 weeks gestation). (A) Seroprevalence with standard errors and (B) boxplots of antibody levels in case and control subjects. Horizontal lines represent medians, boxes represent interquartile range, and lines represent ranges with outliers represented as dots. Antibody prevalences and levels were significantly higher in case than in control subjects (P < .001). Antibody levels according to gravidity in control subjects (C) and case subjects (D). In case and control groups, there was no association between gravidity and antibody levels (P > .17).CC BY-NC · PubMed Central
Figure 2. Antibody levels over gestation could be classified as relatively stable or dynamic. For each individual woman, the mean antibody response over gestation time and standard deviation (SD; ie, how far the individuals IgG response fluctuated from their mean response) was calculated. Use of a cutoff of a SD of 0.1 broadly classified individual woman as having dynamic (SD ≥ 0.1) or relatively stable responses (SD < 0.1). (A) The categorization of relatively stable and dynamic responses to PfAMA1 is shown as a representative example of antimalarial IgG responses throughout pregnancy (each line represents antibody levels in an individual over time). (B) The proportion (%) of dynamic antibody responses according to longitudinal exposure group. Species-specific cases refers to women who were infected with Plasmodium falciparum or Plasmodium vivax during pregnancy for P. falciparum and P. vivax antigens, respectively. The proportion of women with dynamic responses during pregnancy was associated with species-specific longitudinal exposure groups PfVAR2CSA, P < .001; PfAMA1, P < .001; PfEBA175 P = .24; PfMSP2, P < .001; PfMSP3, P < .001; PvAMA, P = .006.
Figure 2. Antibody levels over gestation could be classified as relatively stable or dynamic. For each individual woman, the mean antibody response over gestation time and standard deviation (SD; ie, how far the individuals IgG response fluctuated from their mean response) was calculated. Use of a cutoff of a SD of 0.1 broadly classified individual woman as having dynamic (SD ≥ 0.1) or relatively stable responses (SD < 0.1). (A) The categorization of relatively stable and dynamic responses to PfAMA1 is shown as a representative example of antimalarial IgG responses throughout pregnancy (each line represents antibody levels in an individual over time). (B) The proportion (%) of dynamic antibody responses according to longitudinal exposure group. Species-specific cases refers to women who were infected with Plasmodium falciparum or Plasmodium vivax during pregnancy for P. falciparum and P. vivax antigens, respectively. The proportion of women with dynamic responses during pregnancy was associated with species-specific longitudinal exposure groups PfVAR2CSA, P < .001; PfAMA1, P < .001; PfEBA175 P = .24; PfMSP2, P < .001; PfMSP3, P < .001; PvAMA, P = .006.CC BY-NC · PubMed Central
Figure 3. Examples of individuals with relatively stable and dynamic antimalarial responses. Each woman was classified as having dynamic (antibody optical density [OD] standard deviation [SD] ≥ 0.1) or relatively stable responses (antibody OD SD < 0.1). Relatively stable responses to PfAMA1, PfVAR2CSA, and PvAMA1 in the same 10 women (one color is the same woman). Dynamic responses to Plasmodium falciparum antigens PfAMA1, PfVAR2CSA in another 10 women, and dynamic responses to Plasmodium vivax antigens in an additional 10 women (with the exception of the yellow individual who had dynamic responses for all 3 antigens).
Figure 3. Examples of individuals with relatively stable and dynamic antimalarial responses. Each woman was classified as having dynamic (antibody optical density [OD] standard deviation [SD] ≥ 0.1) or relatively stable responses (antibody OD SD < 0.1). Relatively stable responses to PfAMA1, PfVAR2CSA, and PvAMA1 in the same 10 women (one color is the same woman). Dynamic responses to Plasmodium falciparum antigens PfAMA1, PfVAR2CSA in another 10 women, and dynamic responses to Plasmodium vivax antigens in an additional 10 women (with the exception of the yellow individual who had dynamic responses for all 3 antigens).CC BY-NC · PubMed Central
Figure 4. Anti–Plasmodium falciparum levels increase with each successive P. falciparum infection. Multivariable linear mixed-effects modeling of the association between antibody levels and number of episodes in species-specific cases (n = 94 and n = 83 for P. falciparum and P. vivax analysis, respectively). The coefficients (95% confidence interval [CI]) for the estimated mean increase in antibody levels per increase in P. falciparum episode number were as follows: PfVAR2CSA 0.03 (0.01–0.05), P = .011; PfAMA1 0.05 (0.02–0.08), P < .001; PfEBA175 0.05 (0.02–0.07) P < .001; PfMSP2 0.02 (0.003–0.04), P = .025; PfMSP3 0.018 (−0.001 to 0.04), P = .063; PvAMA1 − 0.0004 (−0.01 to 0.01), P = .96; measles −0.003 (−0.015 to 0.01), P = .63.
Figure 4. Anti–Plasmodium falciparum levels increase with each successive P. falciparum infection. Multivariable linear mixed-effects modeling of the association between antibody levels and number of episodes in species-specific cases (n = 94 and n = 83 for P. falciparum and P. vivax analysis, respectively). The coefficients (95% confidence interval [CI]) for the estimated mean increase in antibody levels per increase in P. falciparum episode number were as follows: PfVAR2CSA 0.03 (0.01–0.05), P = .011; PfAMA1 0.05 (0.02–0.08), P < .001; PfEBA175 0.05 (0.02–0.07) P < .001; PfMSP2 0.02 (0.003–0.04), P = .025; PfMSP3 0.018 (−0.001 to 0.04), P = .063; PvAMA1 − 0.0004 (−0.01 to 0.01), P = .96; measles −0.003 (−0.015 to 0.01), P = .63.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 101

Metadata

Authors
Fowkes, F. J., McGready, R., Cross, N. J., Hommel, M., Simpson, J. A., Elliott, S. R., Richards, J. S., Lackovic, K., Viladpai-Nguen, J., Narum, D., Tsuboi, T., Anders, R. F., Nosten, F., & Beeson, J. G.
Affiliations
  • Burnet Institute (AU)
  • Mahidol University (TH)
  • The University of Melbourne (AU)
  • Walter and Eliza Hall Institute of Medical Research (AU)
  • Shoklo Malaria Research Unit (TH)
  • National Institutes of Health (US)
  • Ehime University (JP)
  • La Trobe University (AU)
Corresponding author
Fowkes, Freya JI.
Venue
The Journal of Infectious Diseases
Published
2012-09-10
Volume
206
Issue
10
Pages
1612-1621
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2102871981
Cited by
101
References
32
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 14 · 2021: 8 · 2020: 3 · 2019: 6 · 2018: 7 · 2017: 5 · 2016: 15 · 2015: 11 · 2014: 12 · 2013: 6 · 2012: 2
FWCI
9.57
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • The Journal of Infectious Diseases (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
Funders
  • Wellcome Trust
  • University of Oxford
  • Medical Research Council
  • National Health and Medical Research Council
  • Japan Society for the Promotion of Science (23406007)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
  • Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
Keywords
malaria in pregnancy, anti-malarial antibodies, Plasmodium falciparum, Plasmodium vivax, merozoite antigens, antibody half-life, immunological memory, reinfection, antibody boosting, vaccine-induced immunity, malaria vaccine development
MeSH terms
Adult, Antibodies, Protozoan, Antimalarials, Chloroquine, Female, Humans, Immunoglobulin G, Plasmodium falciparum, Plasmodium vivax, Pregnancy, Thailand, Pregnancy Complications, Parasitic, Case-Control Studies, Malaria, Falciparum, Malaria, Vivax, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women. https://app.cochat.ai/papers/10.1093/infdis/jis566
The paper
Fowkes, F. J., McGready, R., Cross, N. J., Hommel, M., Simpson, J. A., Elliott, S. R., Richards, J. S., Lackovic, K., Viladpai-Nguen, J., Narum, D., Tsuboi, T., Anders, R. F., Nosten, F., & Beeson, J. G. (2012). New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jis566

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.